CanSinoBIO inhaled Covid vaccine candidate triggers immune response - early trial
Published: Jul 28, 2021 8:51 AM
An inhaled version of CanSino Biologics' (CanSinoBIO) Covid-19 vaccine triggered immune responses without serious side effects, an early-stage clinical trial showed.
The two-dose candidate requires lower dosages than the injected version and could help CanSinoBIO boost its production capacity, the company's chief executive said in April.
Two inhaled doses of the Ad5-nCoV vaccine, given 28 days apart, elicited...
View Comments0
Report this comment
500 characters remaining
Are you sure you want to delete this comment?
This action cannot be undone.